JP2007530584A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007530584A5 JP2007530584A5 JP2007505204A JP2007505204A JP2007530584A5 JP 2007530584 A5 JP2007530584 A5 JP 2007530584A5 JP 2007505204 A JP2007505204 A JP 2007505204A JP 2007505204 A JP2007505204 A JP 2007505204A JP 2007530584 A5 JP2007530584 A5 JP 2007530584A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antibody
- cancer
- integrin
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55642104P | 2004-03-24 | 2004-03-24 | |
| US55642204P | 2004-03-24 | 2004-03-24 | |
| US60/556,421 | 2004-03-24 | ||
| US60/556,422 | 2004-03-24 | ||
| US62504904P | 2004-11-03 | 2004-11-03 | |
| US60/625,049 | 2004-11-03 | ||
| US65109805P | 2005-02-07 | 2005-02-07 | |
| US60/651,098 | 2005-02-07 | ||
| US65751405P | 2005-02-28 | 2005-02-28 | |
| US60/657,514 | 2005-02-28 | ||
| PCT/US2005/009939 WO2005092073A2 (en) | 2004-03-24 | 2005-03-24 | Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007530584A JP2007530584A (ja) | 2007-11-01 |
| JP2007530584A5 true JP2007530584A5 (https=) | 2008-05-08 |
| JP4857259B2 JP4857259B2 (ja) | 2012-01-18 |
Family
ID=35056776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007505204A Expired - Fee Related JP4857259B2 (ja) | 2004-03-24 | 2005-03-24 | 癌細胞増殖を阻害するための抗α５β１抗体の使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7662384B2 (https=) |
| EP (1) | EP1755659B1 (https=) |
| JP (1) | JP4857259B2 (https=) |
| KR (1) | KR20070009637A (https=) |
| AT (1) | ATE531388T1 (https=) |
| AU (1) | AU2005226736B2 (https=) |
| BR (1) | BRPI0509177A (https=) |
| CA (1) | CA2560508A1 (https=) |
| DK (1) | DK1755659T3 (https=) |
| ES (1) | ES2376556T3 (https=) |
| IL (1) | IL178042A (https=) |
| NO (1) | NO20064794L (https=) |
| NZ (1) | NZ549893A (https=) |
| WO (1) | WO2005092073A2 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090220508A1 (en) | 2006-03-15 | 2009-09-03 | Alexion Pharmaceuticals, Inc. | Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement |
| NZ615012A (en) * | 2006-03-21 | 2015-11-27 | Genentech Inc | Combinatorial therapy involving alpha5beta1 antagonists |
| WO2007114851A1 (en) * | 2006-04-04 | 2007-10-11 | The Board Of Trustees Of The University Of Illinois | Methods and compositions to induce cell death of invasive tumors |
| EA200802348A1 (ru) * | 2006-05-24 | 2009-08-28 | Байер Шеринг Фарма Акциенгезельшафт | ЧЕЛОВЕЧЕСКИЙ ВЫСОКОАФФИННЫЙ И ГУМАНИЗИРОВАННЫЙ АНТИ-α5β1 ИНТЕГРИН С ФУНКЦИЕЙ БЛОКИРУЮЩЕГО АНТИТЕЛА С ОСЛАБЛЕННОЙ ИММУНОГЕННОСТЬЮ |
| WO2008061377A1 (en) * | 2006-11-22 | 2008-05-29 | Centre Hospitalier De L'universite De Montreal | Novel receptor for cd40l and uses thereof |
| WO2009018226A2 (en) * | 2007-07-27 | 2009-02-05 | Facet Biotech Corporation | Pharmaceutical combinations comprising a tyrosine kinase inhibitor and an antibody against integrin alpha 1 beta 5 (cd49e) |
| MY151191A (en) * | 2007-09-26 | 2014-04-30 | Genentech Inc | Novel antibodies |
| EP2650017A3 (en) * | 2008-02-05 | 2014-01-22 | Bristol-Myers Squibb Company | Alpha 5 - beta 1 antibodies and their uses |
| CA2748158A1 (en) | 2008-12-23 | 2010-07-01 | Astrazeneca Ab | Targeted binding agents directed to .alpha.5.beta.1 and uses thereof |
| NZ594343A (en) * | 2009-03-25 | 2013-10-25 | Genentech Inc | Novel anti-alpha5beta1 antibodies and uses thereof |
| US20110319335A1 (en) | 2010-06-23 | 2011-12-29 | Xiaodong Feng | Combined administration of integrin receptor antagonists for anti-angiogenic therapy |
| CN107233569B (zh) | 2011-10-25 | 2021-08-31 | 普罗西纳生物科学有限公司 | 抗体制剂和方法 |
| US8946159B2 (en) * | 2011-12-22 | 2015-02-03 | California Northstate College Of Pharmacy, Llc | Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment |
| NO2760138T3 (https=) | 2012-10-01 | 2018-08-04 | ||
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| JP7382232B2 (ja) | 2017-05-02 | 2023-11-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤 |
| WO2020081408A1 (en) | 2018-10-18 | 2020-04-23 | Merck Sharp & Dohme Corp. | Formulations of anti-rsv antibodies and methods of use thereof |
| MX2021004928A (es) | 2018-10-31 | 2021-06-08 | Merck Sharp & Dohme Llc | Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos. |
| EP3876990A4 (en) | 2018-11-07 | 2023-09-06 | Merck Sharp & Dohme LLC | CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES |
| WO2025106725A2 (en) * | 2023-11-15 | 2025-05-22 | Morphic Therapeutic, Inc. | HUMAN ANTI-α5β1 ANTIBODIES AND USES THEREOF |
| WO2025106724A2 (en) * | 2023-11-15 | 2025-05-22 | Morphic Therapeutic, Inc. | USE OF ANTI-α5β1 ANTIBODIES IN THE TREATMENT OF PULMONARY HYPERTENSION AND HEART FAILURE |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4704366A (en) * | 1984-06-22 | 1987-11-03 | Bio-Rad Laboratories, Inc. | Process for binding IgG to protein A |
| JPS61134325A (ja) * | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4801687A (en) * | 1986-10-27 | 1989-01-31 | Bioprobe International, Inc. | Monoclonal antibody purification process using protein A |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| CA2082160C (en) * | 1991-03-06 | 2003-05-06 | Mary M. Bendig | Humanised and chimeric monoclonal antibodies |
| AU669124B2 (en) * | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
| GB9125979D0 (en) * | 1991-12-06 | 1992-02-05 | Wellcome Found | Antibody |
| CA2130436C (en) * | 1992-02-19 | 2001-04-10 | John S. Abrams | Cloning and expression of humanized monoclonal antibodies against human interleukin-4 |
| US5639641A (en) * | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| ATE250138T1 (de) | 1992-10-29 | 2003-10-15 | Univ Australian | Angiogenese-inhibierende antikörper |
| US5536814A (en) * | 1993-09-27 | 1996-07-16 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
| US5981478A (en) | 1993-11-24 | 1999-11-09 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
| EP0745134A1 (en) | 1994-02-22 | 1996-12-04 | Danafarber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
| DE69516351T2 (de) * | 1994-09-21 | 2000-12-07 | Matsushita Electric Industrial Co., Ltd. | Sekundäre Lithium Feststoffbatterie |
| US5705154A (en) * | 1995-03-08 | 1998-01-06 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
| WO1997033887A1 (en) | 1996-03-15 | 1997-09-18 | Du Pont Pharmaceuticals Company | Spirocycle integrin inhibitors |
| US5922676A (en) * | 1996-09-20 | 1999-07-13 | The Burnham Institute | Methods of inhibiting cancer by using superfibronectin |
| US5846536A (en) | 1996-10-04 | 1998-12-08 | The Regents Of The University Of California | Restoration of normal phenotype in cancer cells |
| WO1998032771A1 (en) | 1997-01-29 | 1998-07-30 | Toray Industries, Inc. | Chimeric proteins, heterodimer complexes thereof and substitute for platelet |
| US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| AU2444899A (en) * | 1998-01-22 | 1999-08-09 | Astrazeneca Ab | Pharmaceutical formulation comprising an antibody and a citrate buffer |
| EP1075543A2 (en) | 1998-04-27 | 2001-02-14 | Sidney Kimmel Cancer Center | Reduced complexity nucleic acid targets and methods of using same |
| US6852318B1 (en) * | 1998-05-08 | 2005-02-08 | The Regents Of The University Of California | Methods for detecting and inhibiting angiogenesis |
| WO1999058139A2 (en) * | 1998-05-08 | 1999-11-18 | The Regents Of The University Of California | Methods for detecting and inhibiting angiogenesis |
| JP2003517816A (ja) | 1999-08-11 | 2003-06-03 | イオス バイオテクノロジー， インコーポレイテッド | 新脈管形成の診断の新規方法、新脈管形成調節因子についてのスクリーニングの組成物および方法 |
| CA2397194C (en) | 2000-01-20 | 2011-05-17 | Mark E. Duggan | Alpha v integrin receptor antagonists |
| CA2397665A1 (en) | 2000-01-24 | 2001-07-26 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
| US7740841B1 (en) * | 2000-01-28 | 2010-06-22 | Sunnybrook Health Science Center | Therapeutic method for reducing angiogenesis |
| US20040259152A1 (en) * | 2000-02-22 | 2004-12-23 | Richard Murray | Novel methods of diagnosing and screening for modulators of tissue remodeling and treating related diseases |
| CA2438030A1 (en) | 2001-02-14 | 2002-10-10 | Protein Design Labs | Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
| JP4741242B2 (ja) * | 2002-11-26 | 2011-08-03 | アボット バイオセラピューティクス コーポレイション | 新脈管形成を調節するα５β１インテグリンへのキメラ及びヒト化抗体 |
| US7276589B2 (en) * | 2002-11-26 | 2007-10-02 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
| JP2007524605A (ja) * | 2003-04-03 | 2007-08-30 | ピーディーエル バイオファーマ，インコーポレイティド | インテグリンα５β１のインヒビターおよび組織顆粒化の制御のためのそれらの使用 |
| CN1816356A (zh) | 2003-05-14 | 2006-08-09 | 免疫原公司 | 药物缀合物组合物 |
-
2005
- 2005-03-24 DK DK05744016.6T patent/DK1755659T3/da active
- 2005-03-24 EP EP05744016A patent/EP1755659B1/en not_active Expired - Lifetime
- 2005-03-24 KR KR1020067021955A patent/KR20070009637A/ko not_active Ceased
- 2005-03-24 JP JP2007505204A patent/JP4857259B2/ja not_active Expired - Fee Related
- 2005-03-24 WO PCT/US2005/009939 patent/WO2005092073A2/en not_active Ceased
- 2005-03-24 CA CA002560508A patent/CA2560508A1/en not_active Abandoned
- 2005-03-24 ES ES05744016T patent/ES2376556T3/es not_active Expired - Lifetime
- 2005-03-24 AT AT05744016T patent/ATE531388T1/de active
- 2005-03-24 NZ NZ549893A patent/NZ549893A/en not_active IP Right Cessation
- 2005-03-24 AU AU2005226736A patent/AU2005226736B2/en not_active Ceased
- 2005-03-24 BR BRPI0509177-2A patent/BRPI0509177A/pt not_active IP Right Cessation
- 2005-03-24 US US11/090,331 patent/US7662384B2/en not_active Expired - Fee Related
-
2006
- 2006-09-12 IL IL178042A patent/IL178042A/en not_active IP Right Cessation
- 2006-10-23 NO NO20064794A patent/NO20064794L/no not_active Application Discontinuation
-
2009
- 2009-12-18 US US12/642,687 patent/US20100291111A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007530584A5 (https=) | ||
| Beatty et al. | The biological underpinnings of therapeutic resistance in pancreatic cancer | |
| RU2007127842A (ru) | Антитела против ангиопоэтина-2 и их применение | |
| Stillebroer et al. | Phase 1 radioimmunotherapy study with lutetium 177–labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma | |
| Chaudhry et al. | Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer | |
| Persson et al. | First 18F-labeled ligand for PET imaging of uPAR: In vivo studies in human prostate cancer xenografts | |
| JP2009506790A5 (https=) | ||
| JP2009539380A5 (https=) | ||
| Wichert et al. | Targeting carbonic anhydrase IX with small organic ligands | |
| Sheffer et al. | Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated antitumoral effect | |
| WO2009114809A1 (en) | Therapies for cancer using isotopically substituted lysine | |
| CA2579523A1 (en) | Atad3a-binding molecules for treatment, detection and prevention of cancer | |
| JP2010534685A (ja) | チロシンキナーゼ阻害剤およびインテグリンα５β１（ＣＤ４９Ｅ）に対する抗体を含む薬学的な組み合わせ | |
| JP2011505371A5 (https=) | ||
| Fortin et al. | Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2: 342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma | |
| AU2003229431B2 (en) | Method for reducing pain using oncolytic viruses | |
| PL374675A1 (en) | Use of urease for inhibiting cancer cell growth | |
| Kulkarni et al. | Papillary thyroid cancer differentiating into anaplastic carcinoma with near-complete response to targeted dabrafenib/trametinib combination therapy | |
| RU2006137360A (ru) | ПРИМЕНЕНИЕ АНТИТЕЛ ПРОТИВ α5β1 ДЛЯ ИНГИБИРОВАНИЯ ПРОЛИФЕРАЦИИ РАКОВЫХ КЛЕТОК | |
| Ferrone et al. | A human high molecular weight-melanoma associated antigen (HMW-MAA) defined by monoclonal antibodies: a useful marker to radioimage tumor lesions in patients with melanoma | |
| WO2024168482A1 (zh) | 7586-3507在制备抗肿瘤药物中的应用 | |
| Hu et al. | Colon cancer-cell-specific drug delivery by gemcitabine conjugated with peptide chain targeting ENO1 | |
| Sivalingam et al. | Targeting the ACE2 receptor using nanomedicine: Novel approach to lung cancer therapy | |
| CN106366190B (zh) | 一种抗人肝癌干细胞的单克隆抗体 | |
| JP2024515100A5 (https=) |